The company’s new products include the confectionery brand Chowie Wowie, wellness brand Rmdy and the beverage brand Everie, which was developed by Fluent, High Park's joint venture with Labatt Breweries of Canada.
High Park will also introduce the U.S. brands Marley Natural and Goodship in the Canadian market, the company said.
Chowie Wowie will offer cannabis-infused chocolates and gummies, with both THC and CBD choices. Rmdy will offer cannabis mints, melts and all-in-one vape pens, while Goodship will introduce itself to the Canadian market with cannabis-infused gourmet chocolates, cooking oil and mints in both THC and CBD varieties.
Everie produces non-alcoholic CBD-infused beverages, while Canaca offers all-in-one vape pens and vape cartridges with pure cannabis THC distillate.
Marley Natural's Marley Green vape cartridges contain CO2 winterized hybrid cannabis oil.
The lineup of Cannabis 2.0 products shipped Monday and is expected to hit shelves at the beginning of 2020, according to Tilray.
“The evolution of the High Park brand portfolio has been in the works over the past year as our team of leading experts conducted research studies on new product formulations and consumer preferences,” Adine Fabiani-Carter, High Park’s chief marketing officer, said in a statement.
“We’ve developed unique brands and products giving Canadian consumers more choice and, most importantly, access to safe, regulated and quality-tested products.”
Tilray Exports Medical Cannabis Extract To Switzerland
Tilray also announced Tuesday that it has successfully exported medical cannabis extracts to Switzerland.
This makes Switzerland the 14th country to distribute Tilray's medical cannabis products.
Tilray said it obtained import and export permits at the beginning of December, and the first shipment arrived in the country Dec. 13. The company also plans to export dried medical cannabis to Switzerland.
“We’re proud to deliver Tilray’s medical cannabis to Swiss patients in need as we continue our expansion into Europe and around the globe,” Sascha Mielcarek, Tilray’s managing director in Europe, said in a statement.
“Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products.”
Tilray announced last week that it obtained GMP certification for its European Union campus in Portugal, which will enable the company to supply cannabis products to international markets.
The stock was down 1.15% at $18 at the time of publication Tuesday.Related Links:
Photo courtesy of Tilray.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.